"Dopamine Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and activate dopamine receptors.
| Descriptor ID |
D018491
|
| MeSH Number(s) |
D27.505.519.625.150.151 D27.505.696.577.150.151
|
| Concept/Terms |
Dopamine Agonists- Dopamine Agonists
- Agonists, Dopamine
- Receptor Agonists, Dopamine
- Dopamine Receptor Agonist
- Agonist, Dopamine Receptor
- Receptor Agonist, Dopamine
- Dopamine Receptor Agonists
- Dopaminergic Agonists
- Agonists, Dopaminergic
- Dopaminergic Agonist
- Agonist, Dopaminergic
- Agonists, Dopamine Receptor
- Dopamine Agonist
- Agonist, Dopamine
|
Below are MeSH descriptors whose meaning is more general than "Dopamine Agonists".
Below are MeSH descriptors whose meaning is more specific than "Dopamine Agonists".
This graph shows the total number of publications written about "Dopamine Agonists" by people in this website by year, and whether "Dopamine Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 1 | 1 |
| 2017 | 3 | 2 | 5 |
| 2018 | 5 | 2 | 7 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Dopamine Agonists" by people in Profiles.
-
Neurotransmitters and Neuropeptides decrease PD-1 in T cells of healthy subjects and patients with hepatocellular carcinoma (HCC), and increase their proliferation and eradication of HCC cells. Neuropeptides. 2021 Oct; 89:102159.
-
Acute transverse myelitis with Dysautonomia following SARS-CoV-2 infection: A case report and review of literature. J Neuroimmunol. 2021 04 15; 353:577523.
-
Endocrinology in the time of COVID-19: Management of pituitary tumours. Eur J Endocrinol. 2020 Jul; 183(1):G17-G23.
-
Neurocovid: Pharmacological Recommendations for Delirium Associated With COVID-19. Psychosomatics. 2020 Nov - Dec; 61(6):585-596.
-
Neuroleptic malignant syndrome in a COVID-19 patient. Brain Behav Immun. 2020 08; 88:28-29.
-
Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies. CNS Spectr. 2020 08; 25(4):502-510.
-
Cariprazine for the treatment of bipolar depression: a review. Expert Rev Neurother. 2019 04; 19(4):317-323.
-
Apomorphine infusion in advanced Parkinson disease. Nat Rev Neurol. 2018 Dec; 14(12):693-694.
-
Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson's disease. Parkinsonism Relat Disord. 2019 04; 61:111-117.
-
Long-term treatment with rotigotine in drug-naïve PSP patients. Acta Neurol Belg. 2019 Mar; 119(1):113-116.